Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 8/20 | 0.67 |
| ▸ | MGLL | Q99685 | 1/20 | 0.62 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.61 |
| ▸ | OPRD1 | P41143 | 7/20 | 0.61 |
| ▸ | IGF1R | P08069 | 1/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.60 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.60 |
| ▸ | DRD2 | P14416 | 5/20 | 0.59 |
| ▸ | DRD3 | P35462 | 4/20 | 0.59 |
| ▸ | DRD1 | P21728 | 1/20 | 0.59 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.59 |
| ▸ | HTR7 | P34969 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28352345 | 1.00 | OPRK1 (0.67) | OPRK1MGLLOPRM1OPRD1IGF1R | |
| SCHEMBL5537554 | 1.00 | OPRK1 (0.67) | OPRK1MGLLOPRM1OPRD1IGF1R | |
| SCHEMBL5544469 | 0.98 | OPRK1 (0.69) | OPRK1MGLLOPRM1OPRD1IGF1R | |
| SCHEMBL5542876 | 0.94 | OPRK1 (0.69) | OPRK1MGLLOPRM1OPRD1IGF1R | |
| SCHEMBL26548204 | 0.94 | MGLL (0.68) | OPRK1MGLLOPRM1OPRD1ALOX15 | |
| SCHEMBL21002079 | 0.94 | MGLL (0.68) | OPRK1MGLLOPRM1OPRD1ALOX15 | |
| SCHEMBL8398287 | 0.94 | MGLL (0.68) | OPRK1MGLLOPRM1OPRD1ALOX15 | |
| SCHEMBL11232474 | 0.91 | DRD2 (0.68) | OPRK1MGLLOPRM1OPRD1ALOX15 | |
| 3-Phenethylphenol SCHEMBL717571 | 0.89 | OPRK1 (0.74) | OPRK1OPRM1OPRD1DRD2DRD3 | |
| SCHEMBL3312922 | 0.88 | CBS (0.62) | OPRK1MGLLOPRM1OPRD1IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102532162-B | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMA CO LTD | 2015-05-27 | — | — | CN | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| CN-1705670-A | 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds | OTSUKA PHARMA CO LTD (JP) | 2005-12-07 | — | — | CN | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | OPRK1 660/4885MGLL 4717/4885OPRM1 518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.